United States - English - NLM (National Library of Medicine)

csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone valerate, quantity: 0.244 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: liquid paraffin; purified water; chlorocresol; cetostearyl alcohol; phosphoric acid; monobasic sodium phosphate dihydrate; cetomacrogol 1000; sodium hydroxide; white soft paraffin - antroquoril is indicated for maintenance therapy for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic eczema, infantile eczema, nummular eczema, anogenital and senile pruritis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, solar dermatitis, statis dermatitis and psoriasis. indications as at 16 august 1999: antroquoril is indicated for maintenance therapy for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic eczema, infantile eczema, nummular eczema, anogenital and senile pruritus, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, solar dermatitis, stasis dermatitis and psoriasis

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone valerate, quantity: 0.244 mg/g - cream - excipient ingredients: purified water; sodium hydroxide; chlorocresol; cetostearyl alcohol; cetomacrogol 1000; phosphoric acid; white soft paraffin; liquid paraffin; monobasic sodium phosphate dihydrate - indications as at 30 april 1991: for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic eczema, infantile eczema, nummular eczema, anogenital and senile pruritus, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, solar dermatitis, stasis dermatitis and psoriasis. celestone -m is indicated for maintenance therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - ointment - excipient ingredients: white soft paraffin; liquid paraffin - topical treatment of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lechen planus, intertrigo and psoriasis. indications as at 26 august 1992: eleuphrat is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - cream - excipient ingredients: phosphoric acid; cetostearyl alcohol; white soft paraffin; sodium hydroxide; cetomacrogol 1000; purified water; liquid paraffin; chlorocresol; monobasic sodium phosphate dihydrate - topical treatment of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. indications as at 26 august 1992: eleuphrat is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - ointment - excipient ingredients: white soft paraffin; liquid paraffin - indications as at 22 november 1995: diprosone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - lotion - excipient ingredients: carbomer 1342; isopropyl alcohol; purified water; sodium hydroxide - indications as at 22 november 1995: diprosone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. diprosone lotion is indicated wherever hair impedes access to the skin in the treatment of corticosteroid-responsive dermatoses particularly on the scalp, chest and underarms, etc. it is also indicated in the treatment of seborrhoea and psoriasis of the scalp.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - cream - excipient ingredients: liquid paraffin; monobasic sodium phosphate dihydrate; phosphoric acid; white soft paraffin; cetomacrogol 1000; cetostearyl alcohol; sodium hydroxide; chlorocresol; purified water - indications as at 22 november 1995: diprosone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis.

United States - English - NLM (National Library of Medicine)

forces of nature - hydrocotyle asiatica1 12c - heals thickened and itchy skin silicea1 6x - reduces inflammation natrum muriaticum1 12x - remedy for eczema iris versicolor1 12c - relieves itchy skin associated with eczema lappa articum1 12c - remedy for eczema ruta graveolens1 12c - relieves itchy skin taraxacum officinale1 6c - remedy for skin eruptions thuja occidentalis1 8x - relieves skin eruptions with itching - for the temporary relief of itching associated with minor skin irritations and rashes which may be due to eczema.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - lotion - excipient ingredients: isopropyl alcohol; purified water; sodium hydroxide; carbomer 1342 - topical treatment of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. eleuphrat lotion is indicated wherever hair impedes access to the skin in the treatment of corticosteroid-responsive dermatoses particularly on the scalp, chest and underarms, etc. it is also indicated in the treatment of seborrhoea and psoriasis of the scalp. indications as at 22 november 1995: eleuphrat is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. these include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. eleuphrat lotion is indicated wherever hair impedes access to the skin in the treatment of corticosteroid-responsive dermatoses particularly on the scalp, chest and underarms, etc. it is also